Clinical advances in molecular biomarkers for cancer diagnosis and therapy

International Journal of Molecular Sciences

Volumn 14, Issue 7, 2013, Pages 14771-14784

  Sethi, Seema ^a   Ali, Shadan ^a   Philip, Philip A ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Advances; Basic; Cancer diagnosis; Clinical; Translational research

Indexed keywords

ABELSON KINASE; ABELSON KINASE 1; ACETYLSALICYLIC ACID; BCR ABL PROTEIN; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; MICRORNA; MICRORNA 155; MICRORNA 17 92; MICRORNA 21; PANITUMUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VEMURAFENIB;

BCR ABL GENE; BRAF GENE; CANCER CELL; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CAPILLARY ELECTROPHORESIS; CELL STRUCTURE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC VALUE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PROTEIN DOMAIN; PYROSEQUENCING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 84880712727     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140714771     Document Type: Review

References (74)

1. Febbo, P.G.; Ladanyi, M.; Aldape, K.D.; de Marzo, A.M.; Hammond, M.E.; Hayes, D.F.; Iafrate, A.J.; Kelley, R.K.; Marcucci, G.; Ogino, S. et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J. Natl. Compr. Canc. Netw. 2011, 9, S1-S32.
2. Ahmad, A.; Aboukameel, A.; Kong, D.; Wang, Z.; Sethi, S.; Chen, W.; Sarkar, F.H.; Raz, A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011, 71, 3400-3409.
3. Ahmad, A.; Sarkar, S.H.; Bitar, B.; Ali, S.; Aboukameel, A.; Sethi, S.; Li, Y.; Bao, B.; Kong, D.; Banerjee, S.et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol. Cancer Ther. 2012, 11, 2193-201.
4. Ali, S.; Almhanna, K.; Chen, W.; Philip, P.A.; Sarkar, F.H. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res.2010,3, 28-47.
5. Ali, S.; Ahmad, A.; Aboukameel, A.; Bao, B.; Padhye, S.; Philip, P.A.; Sarkar, F.H. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett. 2012, 319, 173-181.
6. Ali, S.; Banerjee, S.; Logna, F.; Bao, B.; Philip, P.A.; Korc, M.; Sarkar, F.H. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J. Cell. Physiol. 2012, 227, 3373-3380.
7. Ali, S.; Saleh, H.; Sethi, S.; Sarkar, F.H.; Philip, P.A. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br. J. Cancer 2012, 107, 1354-1360.
8. Azmi, A.S.; Ali, S.; Banerjee, S.; Bao, B.; Maitah, M.N.; Padhye, S.; Philip, P.A.; Mohammad, R.M.; Sarkar, F.H. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am. J. Transl. Res. 2011, 3, 374-382.
9. Bao, B.; Ali, S.; Kong, D.; Sarkar, S.H.; Wang, Z.; Banerjee, S.; Aboukameel, A.; Padhye, S.; Philip, P.A.; Sarkar, F.H. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6, e17850.
10. Li, Y.; Vandenboom, T.G.; Wang, Z.; Kong, D.; Ali, S.; Philip, P.A.; Sarkar, F.H. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70, 1486-1495.
11. Kong, D.; Banerjee, S.; Ahmad, A.; Li, Y.; Wang, Z.; Sethi, S.; Sarkar, F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5, e12445.
12. Kong, D.; Heath, E.; Chen, W.; Cher, M.L.; Powell, I.; Heilbrun, L.; Li, Y.; Ali, S.; Hassan, O.; Hwang, C. et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012, 7, e33729.
13. Sethi, S.; Kong, D.; Land, S.; Dyson, G.; Sakr, W.A.; Sarkar, F.H. Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am. J. Transl. Res. 2013, 5, 200-211.
14. Sethi, S.; Sarkar, F.H. Evolving concept of cancer stem cells: Role of micro-RNAs and their implications in tumor aggressiveness. J. Carcinog. Mutag. 2011, doi:10.4172/2157-2518.S1-005.
15. Ali, S.; Ahmad, A.; Banerjee, S.; Padhye, S.; Dominiak, K.; Schaffert, J.M.; Wang, Z.; Philip, P.A.; Sarkar, F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70, 3606-36\17.
16. Kitkumthorn, N.; Mutirangura, A. Long interspersed nuclear element-1 hypomethylation in cancer: Biology and clinical applications. Clin. Epigenetics 2011, 2, 315-330.
17. Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol.2011, 8, 686-700.
18. Ku, C.S.; Cooper, D.N.; Roukos, D.H. Clinical relevance of cancer genome sequencing. World J. Gastroenterol. 2013, 19, 2011-2018.
19. Ogino, S.; King, E.E.; Beck, A.H.; Sherman, M.E.; Milner, D.A.; Giovannucci, E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am. J. Epidemiol. 2012, 176, 659-667.
20. Staehler, C.F.; Keller, A.; Leidinger, P.; Backes, C.; Chandran, A.; Wischhusen, J.; Meder, B.; Meese, E. Whole miRNome-wide differential co-expression of microRNAs. Genomics Proteomics Bioinforma. 2012, 10, 285-294.
21. Liu, E.T. Molecular oncodiagnostics: Where we are and where we need to go. J. Clin. Oncol. 2003, 21, 2052-2055.
22. Manzeniuk, O.I.; Malakho, S.G.; Pekhov, V.M.; Kosorukova, I.S.; Poltaraus, A.B. Characterization of the universal Russian reagent sets for real-time PCR and its application for molecular oncodiagnostic. Mol. Biol. 2006, 40, 349-356.
23. Demidyuk, I.V.; Shubin, A.V.; Gasanov, E.V.; Kurinov, A.M.; Demkin, V.V.; Vinogradova, T.V.; Zinovyeva, M.V.; Sass, A.V.; Zborovskaya, I.B.; Kostrov, S.V. Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios. PLoS One 2013, 8, e55752.
24. Goldstein, T.; Paull, E.O.; Ellis, M.J.; Stuart, J.M. Molecular pathways: Extracting medical knowledge from high throughput genomic data. Clin. Cancer Res. 2013, doi:10.1158/1078-0432.
25. Liang, Y.; Ridzon, D.; Wong, L.; Chen, C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007, 8, 166.
26. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
27. Jusufovic, E.; Rijavec, M.; Keser, D.; Korosec, P.; Sodja, E.; Iljazovic, E.; Radojevic, Z.; Kosnik, M. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One 2012, 7, e45577.
28. Gall, T.M.; Frampton, A.E.; Krell, J.; Castellano, L.; Stebbing, J.; Jiao, L.R. Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer. Expert. Rev. Mol. Diagn. 2013, 13, 141-145.
29. Liu, R.; Liao, J.; Yang, M.; Shi, Y.; Peng, Y.; Wang, Y.; Pan, E.; Guo, W.; Pu, Y.; Yin, L. Circulating miR-155 expression in plasma: A potential biomarker for early diagnosis of esophageal cancer in humans. J. Toxicol. Environ. Health A 2012, 75, 1154-1162.
30. Garand, R.; Beldjord, K.; Cave, H.; Fossat, C.; Arnoux, I.; Asnafi, V.; Bertrand, Y.; Boulland, M.L.; Brouzes, C.; Clappier, E.; et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2013, 27, 370-376.
31. Gocke, C.D.; Mason, J.; Brusca, L.; Laosinchai-Wolf, W.; Higgs, C.; Newell, H.; Masters, A.; Friar, L.; Karp, J.; Griffiths, M.; et al. Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: Results from a multicenter validation study. Blood Cancer J. 2012, 2, doi:10.1038/bcj.2012.24.
32. Alonso, C.N.; Gallego, M.S.; Rossi, J.G.; Medina, A.; Rubio, P.L.; Bernasconi, A.R.; Zubizarreta, P.A.; Felice, M.S. RT-PCR diagnosis of recurrent rearrangements in pediatric acute lymphoblastic leukemia in Argentina. Leuk Res. 2012, 36, 704-708.
33. Cho, Y.U.; Chi, H.S.; Park, C.J.; Jang, S.; Seo, E.J. Rapid detection of prognostically significant fusion transcripts in acute leukemia using simplified multiplex reverse transcription polymerase chain reaction. J. Korean Med. Sci. 2012, 27, 1155-1161.
34. Jennings, L.J.; Smith, F.A.; Halling, K.C.; Persons, D.L.; Kamel-Reid, S. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch. Pathol. Lab. Med. 2012, 136, 33-40.
35. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-2516.
36. Ravnan, M.C.; Matalka, M.S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther. 2012, 34, 1474-1486.
37. Duldulao, M.P.; Lee, W.; Nelson, R.A.; Li, W.; Chen, Z.; Kim, J.; Garcia-Aguilar, J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann. Surg. Oncol. 2013, 20, 2166-2171.
38. Imamura, Y.; Morikawa, T.; Liao, X.; Lochhead, P.; Kuchiba, A.; Yamauchi, M.; Qian, Z.R.; Nishihara, R.; Meyerhardt, J.A.; Haigis, K.M.; et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 2012, 18, 4753-4763.
39. Hassan, O.; Ahmad, A.; Sethi, S.; Sarkar, F.H. Recent updates on the role of microRNAs in prostate cancer. J. Hematol. Oncol. 2012, 5, 9.
40. Hinton, J.; Callan, R.; Bodine, C.; Glasgow, W.; Brower, S.; Jiang, S.W.; Li, J. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Rev. Mol. Diagn. 2013, 13, 431-443.
41. Li, C.; Li, J.F.; Cai, Q.; Qiu, Q.Q.; Yan, M.; Liu, B.Y.; Zhu, Z.G. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J. Surg. Oncol. 2013, doi:10.1002/jso.23358.
42. Xiao, Y.F.; Yong, X.; Fan, Y.H.; Lu, M.H.; Yang, S.M.; Hu, C.J. microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review). Oncol. Rep. 2013, 30, 535-544.
43. Plaisier, C.L.; Bare, J.C.; Baliga, N.S. miRvestigator: Web application to identify miRNAs responsible for co-regulated gene expression patterns discovered through transcriptome profiling. Nucleic Acids Res. 2011, 39, W125-W131.
44. Wang, Z.; Zhang, J.; Guo, Y.; Wu, X.; Yang, W.; Xu, L.; Chen, J.; Fu, F. A novel electrically magnetic-controllable electrochemical biosensor for the ultra sensitive and specific detection of attomolar level oral cancer-related microRNA. Biosens. Bioelectron. 2013, 45, 108-113.
45. Wang, Y.; Shi, J.; Wu, Y.; Xu, W.; Wang, Q.; Zhang, J.; Jiang, M.; Gu, G. Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application. Tumori 2012, 98, 792-799.
46. Arata, H.; Komatsu, H.; Han, A.; Hosokawa, K.; Maeda, M. Rapid microRNA detection using power-free microfluidic chip: Coaxial stacking effect enhances the sandwich hybridization. Analyst 2012, 137, 3234-3237.
47. Yan, J.; Zhang, N.; Qi, C.; Liu, X.; Shangguan, D. One-step real time RT-PCR for detection of microRNAs. Talanta 2013, 110, 190-195.
48. Swerdlow, S.H.; Campo, E. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed; International Agency for Research on Cancer Press: Lyon, France, 2008.
49. Fan, Y.S. Companion diagnostic testing for targeted cancer therapies: An overview. Genet. Test. Mol. Biomarkers 2013, doi:10.1089/gtmb.2012.0510.
50. Lovly, C.M.; Dahlman, K.B.; Fohn, L.E.; Su, Z.; Dias-Santagata, D.; Hicks, D.J.; Hucks, D.; Berry, E.; Terry, C.; Duke, M. et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012, 7, e35309.
51. Ogino, S.; Galon, J.; Fuchs, C.S.; Dranoff, G. Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 2011, 8, 711-719.
52. Sethi, S.; Sarkar, F.H.; Ahmed, Q.; Bandyopadhyay, S.; Nahleh, Z.A.; Semaan, A.; Sakr, W.; Munkarah, A.; Ali-Fehmi, R. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl. Oncol. 2011, 4, 222-226.
53. Ali-Fehmi, R.; Semaan, A.; Sethi, S.; Arabi, H.; Bandyopadhyay, S.; Hussein, Y.R.; Diamond, M.P.; Saed, G.; Morris, R.T.; Munkarah, A.R. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer 2011, 117, 301-309.
54. Kang, H.W.; Crawford, M.; Fabbri, M.; Nuovo, G.; Garofalo, M.; Nana-Sinkam, S.P.; Friedman, A. A mathematical model for microRNA in lung cancer. PLoS One 2013, 8, e53663.
55. Castelo-Branco, P.; Choufani, S.; Mack, S.; Gallagher, D.; Zhang, C.; Lipman, T.; Zhukova, N.; Walker, E.J.; Martin, D.; Merino, D. et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet Oncol. 2013, 14, 534-542.
56. Hosein, A.N.; Song, S.; McCart Reed, A.E.; Jayanthan, J.; Reid, L.E.; Kutasovic, J.R.; Cummings, M.C.; Waddell, N.; Lakhani, S.R.; Chenevix-Trench, G.; et al. Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. Lab. Invest. 2013, doi:10.1038/labinvest.2013.54.
57. Rao, A.V.; Smith, B.D. Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia? Curr. Hematol. Malig. Rep. 2013, doi:10.1007/s11899-013-0161-6.
58. Falzoi, M.; Mossa, A.; Congeddu, E.; Saba, L.; Pani, L. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. Pharmacogenomics 2010, 11, 559-571.
59. Saghatchian, M.; Mook, S.; Pruneri, G.; Viale, G.; Glas, A.M.; Guerin, S.; Cardoso, F.; Piccart, M.; Tursz, T.; Delaloge, S.; et al. Additional prognostic value of the 70-gene signature (MammaPrint((R))) among breast cancer patients with 4-9 positive lymph nodes. Breast 2013, doi:10.1016/j.breast.2012.12.002.
60. Yousem, S.A.; Dacic, S.; Nikiforov, Y.E.; Nikiforova, M. Pulmonary langerhans cell histiocytosis: Profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013, 143, 1679-1684.
61. Kloos, R.T.; Reynolds, J.D.; Walsh, P.S.; Wilde, J.I.; Tom, E.Y.; Pagan, M.; Barbacioru, C.; Chudova, D.I.; Wong, M.; Friedman, L.; et al. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma gene expression classifier in cytologically indeterminate thyroid nodules? J. Clin. Endocrinol. Metab. 2013, 98, E761-E768.
62. Trent, R.J.; Cheong, P.L.; Chua, E.W.; Kennedy, M.A. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Pathology 2013, doi:10.1097/PAT.0b013e328360b66e.
63. Mian, A.A.; Metodieva, A.; Badura, S.; Khateb, M.; Ruimi, N.; Najajreh, Y.; Ottmann, O.G.; Mahajna, J.; Ruthardt, M. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-411.
64. Khattak, M.; Fisher, R.; Turajlic, S.; Larkin, J. Targeted therapy and immunotherapy in advanced melanoma: An evolving paradigm. Ther. Adv. Med. Oncol. 2013, 5, 105-118.
65. Galvani, E.; Peters, G.J.; Giovannetti, E. EGF receptor-targeted therapy in non-small-cell lung cancer: Role of germline polymorphisms in outcome and toxicity. Future Oncol. 2012, 8, 1015-1029.
66. Ogino, S.; Meyerhardt, J.A.; Irahara, N.; Niedzwiecki, D.; Hollis, D.; Saltz, L.B.; Mayer, R.J.; Schaefer, P.; Whittom, R.; Hantel, A.; et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 2009, 15, 7322-7329.
67. Chia, W.K.; Ali, R.; Toh, H.C. Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat. Rev. Clin. Oncol. 2012, 9, 561-570.
68. Langley, R.E.; Rothwell, P.M. Potential biomarker for aspirin use in colorectal cancer therapy. Nat. Rev. Clin. Oncol. 2013, 10, 8-10.
69. Liao, X.; Lochhead, P.; Nishihara, R.; Morikawa, T.; Kuchiba, A.; Yamauchi, M.; Imamura, Y.; Qian, Z.R.; Baba, Y.; Shima, K.; et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367, 1596-1606.
70. Gavin, P.G.; Colangelo, L.H.; Fumagalli, D.; Tanaka, N.; Remillard, M.Y.; Yothers, G.; Kim, C.; Taniyama, Y.; Kim, S.I.; Choi, H.J.; et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin. Cancer Res. 2012, 18, 6531-6541.
71. Guastadisegni, C.; Colafranceschi, M.; Ottini, L.; Dogliotti, E. Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. Eur. J. Cancer 2010, 46, 2788-2798.
72. Bouchalova, K.; Cizkova, M.; Cwiertka, K.; Trojanec, R.; Friedecky, D.; Hajduch, M. Lapatinib in breast cancer-The predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2010, 154, 281-288.
73. Varga, Z.; Sinn, P.; Fritzsche, F.; von, H.A.; Noske, A.; Schraml, P.; Tausch, C.; Trojan, A.; Moch, H. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 2013, 8, e58483.
74. Sethi, S.; Ali-Fehmi, R.; Franceschi, S.; Struijk, L.; van Doorn, L.J.; Quint, W.; Albashiti, B.; Ibrahim, M.; Kato, I. Characteristics and survival of head and neck cancer by HPV status: A cancer registry-based study. Int J. Cancer 2012, 131, 1179-1186.